StreetInsider.com News Articles

Glaukos Corporation (GKOS) Reiterated at Buy by Stifel After Solid Q3 iDose Volume Diligence

Fri, 16 Oct 2026 07:11:21 -0400

Stifel analyst Thomas Stephan reiterated a Buy rating and $190.00 price target on Glaukos Corporation (NYSE: GKOS).

The analyst commented, "Our 3Q26 iDose volume diligence was solid, with respondents (n=70) posting +11% q/q growth—supporting our base-case view of $81M-$85M in 3Q iDose sales, an encouraging result.Our checks on MA/commercial mix were better-than-expected, showing how these payers are a growing iDose tailwind—which is expected to continue in 2027.Excitement for key iDose innovations —iDose TREX and potential in-office iDose administration—is high. Additionally, the respondents’ iDose patient outcomes continue to be strongly positive.The 3Q26 iDose bar likely is not overly high if Epioxa revenues

Glaukos iDose TR meets primary endpoint in Phase 4 cataract trial

Fri, 09 Oct 2026 07:01:07 -0400

Glaukos Corporation (NYSE: GKOS) announced positive topline results from a Phase 4 clinical trial evaluating its iDose TR implant administered in combination with cataract surgery in patients with open-angle glaucoma or ocular hypertension.

The trial, designated GLK-101-04, met its primary efficacy endpoint. Patients who received iDose TR alongside cataract surgery achieved a mean diurnal intraocular pressure (IOP) reduction of 11.1 mmHg from baseline at three months, compared to 7.4 mmHg for patients who underwent cataract surgery alone. The incremental treatment difference of 3.6 mmHg was statistically significant (p<0.0001).

The study also reported statistically significant superiority across all pre-specified secondary responder analyses. On

Glaukos iDose TR meets primary endpoint in Phase 4 cataract trial

Fri, 09 Oct 2026 07:01:07 -0400

The study also reported statistically significant superiority across all pre-specified secondary responder analyses. On

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Fri, 09 Oct 2026 07:00:00 -0400

Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority and Clinically Meaningful IOP Reduction vs. Cataract Surgery Alone

iDose TR in Combination with Cataract Surgery Demonstrated Robust Mean IOP Reduction of 11.1 mmHg and Favorable Safety Profile Through 3 Months

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Fri, 09 Oct 2026 07:00:00 -0400

Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority and Clinically Meaningful IOP Reduction vs. Cataract Surgery Alone

iDose TR in Combination with Cataract Surgery Demonstrated Robust Mean IOP Reduction of 11.1 mmHg and Favorable Safety Profile Through 3 Months

Glaukos licenses retinal biologic RO-104 from RevOpsis Therapeutics

Thu, 08 Oct 2026 07:00:31 -0400

Glaukos Corporation (NYSE: GKOS) has entered into an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a tri-specific biologic targeting neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO).

RO-104 is designed to simultaneously block VEGF-A and VEGF-C while inhibiting Ang-2, three angiogenic pathways associated with vascular disease progression. According to the press release, RO-104 has shown preclinical efficacy in animal models compared to approved anti-VEGF therapeutics.

The agreement also grants Glaukos exclusive rights to RevOpsis' RevMod platform for the discovery and development of up to four additional retinal biologic

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Thu, 08 Oct 2026 07:00:00 -0400

License agreement also grants Glaukos exclusive rights to the RevMod™ platform for the discovery and development of up to four additional next-generation biologics for various retinal diseases

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Thu, 08 Oct 2026 07:00:00 -0400

License agreement also grants Glaukos exclusive rights to the RevMod™ platform for the discovery and development of up to four additional next-generation biologics for various retinal diseases

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The

Form 4 GLAUKOS Corp For: Oct 05 Filed by: Navratil Tomas

Wed, 07 Oct 2026 19:08:00 -0400

si-local-file:///var/storage/secattach/20261007/27162219.html

Glaukos reports three-year trial data for Epioxa keratoconus therapy

Wed, 07 Oct 2026 16:07:04 -0400

Glaukos Corporation (NYSE: GKOS) announced results from a long-term Phase 3 extension study evaluating its Epioxa corneal cross-linking therapy for keratoconus, showing sustained efficacy and safety outcomes three years after a single treatment.

The extension study, designated GLK-202-03, followed patients who completed the Phase 3 GLK-202-02 trial. A total of 38 eyes from 35 subjects participated, with 92% completing the three-year visit. No additional intervention was administered during the extension period.

Treated eyes showed a sustained 1.9 diopter improvement in maximum corneal curvature from baseline at the three-year mark. On visual acuity, 29% of treated eyes gained two or more lines of

Glaukos reports three-year trial data for Epioxa keratoconus therapy

Wed, 07 Oct 2026 16:07:04 -0400

Treated eyes showed a sustained 1.9 diopter improvement in maximum corneal curvature from baseline at the three-year mark. On visual acuity, 29% of treated eyes gained two or more lines of

Glaukos reports three-year trial data for Epioxa keratoconus therapy

Wed, 07 Oct 2026 16:07:04 -0400

Treated eyes showed a sustained 1.9 diopter improvement in maximum corneal curvature from baseline at the three-year mark. On visual acuity, 29% of treated eyes gained two or more lines of

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Wed, 07 Oct 2026 16:05:00 -0400

Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sight-threatening corneal disease that remains significantly undiagnosed and undertreated. The extension

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Wed, 07 Oct 2026 16:05:00 -0400

Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sight-threatening corneal disease that remains significantly undiagnosed and undertreated. The extension

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

Wed, 07 Oct 2026 07:00:00 -0400

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026.

A link to the live webcast will be available on the company’s website at

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

Wed, 07 Oct 2026 07:00:00 -0400

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026.

A link to the live webcast will be available on the company’s website at

Form 144 GLAUKOS Corp Filed by: Navratil Tomas

Mon, 05 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261005/27148821.html

Glaukos Corporation (GKOS) Reiterated at Buy by Stifel After 'Highly Bullish' Epioxa Survey

Fri, 02 Oct 2026 07:56:36 -0400

Stifel analyst Thomas Stephan reiterated a Buy rating and $190.00 price target on Glaukos Corporation (NYSE: GKOS).

The analyst commented, "Our Epioxa survey (n=21) was highly bullish, with total procedures increasing from 31 in 2Q26 to 124 in 3Q26 (up 4x). This would imply 3Q26 Epioxa sales of $44M, but even a more conservative 3x assumption yields $30M-$35M—a significant beat.The respondents' estimate of 310 total 4Q26 Epioxa eyes (2.5x q/q) is even more bullish, yet moderately haircutting that growth (2x q/q instead) still drives robust 4Q26 Epioxa sales of $65M-$70M off the potential $30M- $35M 3Q26 base. Our checks around Epioxa

Form 4 GLAUKOS Corp For: Sep 25 Filed by: Navratil Tomas

Mon, 28 Sep 2026 18:24:00 -0400

si-local-file:///var/storage/secattach/20260928/27115738.html

Form 144 GLAUKOS Corp Filed by: Navratil Tomas

Fri, 25 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260925/27107468.html

Glaukos partners with Stephen Curry on keratoconus awareness campaign

Wed, 23 Sep 2026 07:02:18 -0400

Glaukos Corporation (NYSE: GKOS) has launched a disease awareness campaign called "Could it be KC?" in partnership with NBA player Stephen Curry, aimed at improving recognition and earlier detection of keratoconus, a progressive corneal disease.

Curry, who has been diagnosed with keratoconus, will share his personal experience with the condition as part of the campaign. "For a long time, I got used to just getting by, squinting and brushing off headaches, without realizing anything was wrong with my eyes," Curry said. "When I was diagnosed with keratoconus, it was scary, but I knew I couldn't ignore it and asked for help."

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

Wed, 23 Sep 2026 07:00:00 -0400

New Campaign Aims to Raise Awareness, Educate Patients and Families, and Promote Earlier Detection and Diagnosis

Curry to Share His Personal Journey Living with Keratoconus to Empower Individuals to Prioritize Proactive Eye Care and Recognize the Importance of Early Detection

Could it be KC? Campaign and Curry Partnership Underscore Glaukos’ Commitment to Addressing Keratoconus Underdiagnosis and Undertreatment

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

Wed, 23 Sep 2026 07:00:00 -0400

New Campaign Aims to Raise Awareness, Educate Patients and Families, and Promote Earlier Detection and Diagnosis

Curry to Share His Personal Journey Living with Keratoconus to Empower Individuals to Prioritize Proactive Eye Care and Recognize the Importance of Early Detection

Could it be KC? Campaign and Curry Partnership Underscore Glaukos’ Commitment to Addressing Keratoconus Underdiagnosis and Undertreatment

Form 4 GLAUKOS Corp For: Sep 16 Filed by: Navratil Tomas

Fri, 18 Sep 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260918/27081383.html

Form 144 GLAUKOS Corp Filed by: Navratil Tomas

Wed, 16 Sep 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260916/27070493.html